On May 22, Morgan Stanley lowered its price target for Weride Inc. (NASDAQ:WRD) stock from $23 to $13, but maintained its overweight rating on the stock.
Tim Hsiao of Morgan Stanley has high volatility in the Chinese robot market, thus reducing Weride's price target. The company's revenue increased by only 1.8% in the first quarter of 2025, indicating a slower overall growth. Weride faces competition in the autonomous driving market, especially from radical OEMs entering the Robotaxi business.
Weride Inc. (NASDAQ:WRD) focuses on long-term operation with its global expansion. The company partnered with Uber to receive an additional $100 million in stock investment and agreed to provide global taxi services in 15 new cities. The company conducted its first driverless Robotaxi test in Abu Dhabi, expanding its services in the UAE. Weride now has an automated mobile service in three cities in China after launching its services in the central Guangzhou region. The company also enters European countries including Switzerland, Spain and France.
However, Hsiao cuts its 2025-2026 volume forecast for Robobus and Robosweeper Business for Weride. Analysts believe that WRD's "severe stock price changes" have reflected the fluctuations in China's robotics market in the past three months. Despite such forecasts, analysts are still constructive about Weride's long-term prospects and collaboration with Uber overseas.
Weride Inc. (NASDAQ:WRD) provides autonomous driving products and services to different markets to meet the transportation needs of a range of use cases on open roads, including the mobility, logistics and health industries. Its leading products and services include Robotaxi, Robobus, Robovan and Robosweepers.
Although we acknowledge the potential growth of WRD, our belief is that some AI stocks have greater returns and limited downside risks. If you are looking for AI stocks that are more promising than WRD and have 100x upward potential, check out our report Cheapest AI stocks.
Read next: Hedge funds are buying 30 best stocks, according to billionaires and 15 small healthcare stocks.
Disclosure. Nothing.